Sai Parenterals Limited · NSE:SAIPARENT
Sai Parenterals — Q1 FY2027 Earnings Presentation
58 slides from Sai Parenterals's earnings presentation, Aug 12, 2026
Slide 1: Regulation 30 disclosure cover letter
Date: 12th August, 2026 To, The Manager The Manager, BSE Limited NSE Limited, P. J. Towers, Dalal Street Exchange Plaza, Bandra Kurla Complex, Mumbai-400001 Bandra (E), Mumbai- 400051. (BSE Scrip Code: 544742) (NSE Symbol: SAIPARENT) Dear Sir/Madam, Unit: Sai Parenterals Limited Sub: Disclosure unde
Slide 2: Investor Presentation - June 2026
Sai Parenterals Limited Investor Presentation - June 2026
Slide 3: Safe Harbour
Safe Harbour This presentation and the accompanying slides (the “Presentation”), which have been prepared by Sai Parenterals Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any secu
Slide 4: Company Overview
SAL ageNERALS, ivanse Company Overview
Slide 5: Company Snapshot
Company Snapshot A global IP-led pharmaceutical platform Integrated CDMO and branded generics enterprise, focused on injectables and oral dosage forms for regulated and semi-regulated markets 302 599+ 67 >50% 6 1,160 mn manufacturing facilities Installed capacity, units products registrations dossie
Slide 6: Two Business Verticals, One Platform
Two Business Verticals, One Platform TWO BUSINESS VERTICALS CDMO Products & Services 37% 1 Branded Generic Formulations 2 CDMO Products & Services 87% 80% 95% • Off-patent formulations under the Company’s • End-to-end contract development and own brands — sold domestically to government manufacturin
Slide 7: Product Portfolio and Export Revenue Mix
Product Portfolio and Export Revenue Mix Across nine therapeutic areas In Australia and New Zealand Weighted to recurring demand 302 Products in the commercial 526 SKUs under exclusive The portfolio is weighted towards chronic and sub- chronic therapies involving long-term, repeat treatment, portfol
Slide 8: Structural Moats and Operating Advantages
Structural Moats and Operating Advantages Diversified formulations player Established track record across dosage forms, therapeutic areas, geographies and channels since 2016. 1 A near-term capex programme* Accredited manufacturing base A Rs. 571 crore capex programme, of which the 7 2 Facilities ca
Slide 9: Evolution of the Business
Evolution of the Business Incorporation of Incorporation of SAI Parenteral’s • Incorporation of Achieved a Acquired Revat • Set up of Sai • Completed IPO Revat Laboratories Sai Parenteral's Pvt acquisition of 100% Revat turnover of Laboratories Pvt Parenterals Pte. in March 2026 Laboratories Pvt ₹10
Slide 10: Board of Directors
Board of Directors • 31+ years of pharmaceutical industry • Holds Bachelor's, Master's and Ph.D. experience with deep expertise in degrees in Chemistry, with over 34 years manufacturing and commercial of experience in the pharmaceutical operations. industry. • He provides strategic direction, overse
Slide 11: Promoters and Business Leadership
Promoters and Business Leadership Sai Parenterals Limited • 31+ years of pharmaceutical industry experience with deep expertise in • Over 14 years of pharmaceutical industry manufacturing and commercial experience across procurement, operations. technical operations, and quality-driven • He provides
Slide 12: Experienced Promoters and Senior Management
Experienced Promoters and Senior Management Sai Parenteral’s Limited • Over 15 years of experience in • Legal professional with expertise in pharmaceutical manufacturing, with corporate & commercial law, criminal prior experience at Concord Drugs, and tax litigation, and regulatory Nectar Laboratori
Slide 13: Proposed Variation in IPO Proceeds
Proposed Variation in IPO Proceeds
Slide 14: Proposed Variation in Utilization of IPO Proceeds
Proposed Variation in Utilization of IPO Proceeds Amount to be Revised amount funded from Revised timeline S. No. Objects Amount / details of variation after variation net proceeds for utilisation (Rs. cr) (Rs. cr) Original objects of the issue as stated in the Prospectus Rs. 83.8 cr reallocated to
Slide 15: New Greenfield Injectable Facility - Rationale
New Greenfield Injectable Facility - Rationale 1 2 3 HILTP 3,100 sq yd >15,000 sq yd A changed regulatory An asset already under A footprint constraint position in Hyderabad construction Under the Hyderabad Industrial Lands The Jeedimetla site (Unit I and II) is ~3,100 sq yd, Saicriti Pharma’s facil
Slide 16: Two Transactions, One Investment Thesis
Two Transactions, One Investment Thesis Particulars Transaction 1 — new injectable facility Transaction 2 — research and development centre Acquirer Sai Parenterals Limited Sai Parenterals Limited Saicriti Pharma Private Limited — critical-care injectable facility under Prathyak Laboratories Private
Slide 17: Acquisitions over Upgradation — the Strategic Case
Acquisitions over Upgradation — the Strategic Case AS SET OUT IN THE PROSPECTUS AS NOW PROPOSED* WHAT IT CHANGES Upgrade Units I & II to EU-GMP, 57 to 105 Acquire 60% of Saicriti’s facility, 154.66 mn ~47% more capacity, EU-GMP plus USFDA, Injectable mn units; Rs. 83.83 cr; completion Mar units; sam
Slide 18: Corporate Structure
Corporate Structure Sai Parenterals Limited 100% 75% 100% 60% 60% Prathyak Laboratories Revat Laboratories SP Analytics Sai Parenterals Saicriti Pharma Pvt. Ltd. Pvt. Ltd. Private Limited Private Limited Pte Limited 60% — held by Sai Parenterals Ltd 60% — held by Sai Parenterals India India Singapor
Slide 19: Manufacturing & Regulatory Platform
Manufacturing & Regulatory Platform
Slide 20: Current Manufacturing and Research Infrastructure
Current Manufacturing and Research Infrastructure Sterile Injectables Facility Penicillin Injectable Facility Oral Solid Dosage Facility (Jeedimetla, Telangana) (Jeedimetla, Telangana) (Bhongir, Telangana) Cephalosporin Facility Revat Unit Noumed Pharmaceuticals (Bollaram, Telangana) (Ongole, Andhra
Slide 21: Current Manufacturing Footprint and Utilisation
Current Manufacturing Footprint and Utilisation Installed capacity FY26 utilisation FY26 utilization scale Key Dosage forms (mn units) Unit I Liquid injections, sterile non-beta 42 77% Jeedimetla, TS lactam dry powder injections, To be discontinued pre-filled syringes Unit II Sterile penicillin dry
Slide 22: Capacity Utilisation Trend
Capacity Utilisation Trend Capacity Utilisation (%) Group-wide capacity Utilisation (%) 100 63% 90 Capacity utilization trend: 80 53% 70 44% • Unit II (sterile penicillin) runs near full at 95% in H1FY26; 60 50 Unit III (oral solids, TGA) scaled from 24.77% in FY23 to 40 87% in H1FY26 on export dema
Slide 23: Accreditation: The Road Ahead
Accreditation: The Road Ahead Pre-expansion Post-expansion Pre-upgrade Facility Post-upgrade accreditation Capex (Rs. cr) Target completion capacity capacity accreditation To be On commissioning of Unit I (Injectables) 42 mn GMP Not applicable — discontinued the new facility To be On commissioning o
Slide 24: R&D Capabilities
R&D Capabilities R&D Engine • SP Analytics, the Company’s dedicated R&D subsidiary, drives novel formulation development and process optimisation, and prepares and submits dossiers for the EU and other regulated and semi-regulated markets — capability that also underpins the CDMO business 01 Facilit
Slide 25: Business Model and Revenue Engines
Business Model and Revenue Engines
Slide 26: Three Complementary Growth Engines
Three Complementary Growth Engines CDMO Exports Branded Generics Noumed Platform AUSTRALIA & NEW ZEALAND Regulated-market access Partnering customers across Domestic branded formulations through Noumed, with product development, and institutional supply across longstanding pharmacy-chain technology
Slide 27: CDMO Exports
CDMO Exports Formulation Stability Dossier Regulatory Tech transfer Commercial Approval development studies compilation filing back to us supply Revenue event 1 — development fee Revenue event 2 — every batch, for the life of the registration THE CYCLE IS LONG AND THE PAYBACK IS DURABLE WHY OUR CDMO
Slide 28: Branded Generics: Domestic and Export
Branded Generics: Domestic and Export Domestic Trade generics sold to Customers: central and state Tenders from health Longer working-capital cycle distributors without field government agencies, departments in AP, by construction — quality promotion, and branded public and private hospitals, Telang
Slide 29: Noumed: Two Income Streams
Noumed: Two Income Streams Private-label OTC and prescription products supplied to Pharmacy chains contract Noumed for 3PL and logistics 01 Australian and New Zealand pharmacy chains under exclusive to distribute their supplied products 01 long-term agreements SERVICE AND FEE INCOME PRODUCT SUPPLY 1
Slide 30: The Noumed Platform
SAT PARENTERALS LIMITED The Noumed Platform
Slide 31: Why We Acquired Noumed
Why We Acquired Noumed Noumed is an Australia-based supplier of private-label OTC products to retail pharmacy chains, operating in NZ too via its subsidiary Noumed Pharmaceuticals Limited offering both prescription and OTC products. 01 02 03 Turnkey CDMO platform Vertical integration potential Regis
Slide 32: A Full Turnkey Platform
A Full Turnkey Platform Own the IP 〉 Manufacture (Phase 1) 〉 Release the batch 〉 Distribute for the client Today From Q4FY27 Today Today The only organisation in Australia offering the full turnkey solution to multinational pharmaceutical companies OTC portfolio supported by state hospital tenders a
Slide 33: The Australian Pharmacy Model
The Australian Pharmacy Model Originator We own TGA approval Private-label Pharmacy chain patent expires the dossier as first generic supply agreement retails the brand Controlled by Sai Parenterals and Noumed We hold the marketing authorisation We also hold the inventory and the logistics As regist
Slide 34: Customers and Contracts
Customers and Contracts Wesfarmers Health EBOS Group Top-20 ASX listed Top-150 ASX listed Supplied through the Priceline private-label Supplied through the TerryWhite Chemmart banner and the Pharmacy Health generic banner and the Pharmacy Choice generic banner. brand. Operates across Australia, New
Slide 35: Adelaide Facility: Margin Impact
Adelaide Facility: Margin Impact Why in-house manufacturing matters Supply-chain resilience A local manufacturing base reduces reliance on international supply chains and improves continuity for essential products. Margin expansion In-house production lowers procurement, logistics, import-duty and w
Slide 36: The Registration Library
The Registration Library Time to launch in a new export market With an Australian Dossier Without the Library 451+ IP dossiers acquired with Noumed Assembled over five years through in-licensing, portfolio 6 to 9 to 24 purchases and organic development months months 88 + 5 dossier approvals in FY26
Slide 37: SPL + Noumed = Synergies for Growth
SPL + Noumed = Synergies for Growth SPL NOUMED SYNERGIES Proven manufacturing track record; exports up from 3% of revenue from Strong Australian presence with exclusive Supports expansion of SPL’s global CDMO Commercial operations in FY23 to 63% in FY26; long- pharmacy-chain agreements; New business
Slide 38: Growth Strategy and Outlook
PARENTERALS LIMITED Growth Strategy and Outloo
Slide 39: The Global Market Opportunity
The Global Market Opportunity Global injectable market Global CDMO market Global generics market • ~29% of the global pharmaceutical market by • USD 297 billion in 2025, forecast to exceed USD • 50.8% of the total pharmaceutical market by value in 2024 609 billion by 2033 (9.4% CAGR) revenue in 2024
Slide 40: India: A Generics-Led, Affordability-Driven Market
India: A Generics-Led, Affordability-Driven Market ~90% 16,000+* Of Indian drug consumption by value Jan Aushadhi (PMBJP) stores Generics dominate the domestic pharmaceutical market Up from fewer than 100 in 2014 1,77,617* Ayushman Arogya Mandirs Expanding accessibility alongside affordability Pradh
Slide 41: Our Growth Levers
Our Growth Levers Execute the ongoing capex Scale CDMO & exports 1 ~Rs. 571 crore programme 2 Leverage the dossier library • Leverage 67 dossiers under development, plus Australian • Complete the new EU-GMP injectable facility outside the ORR dossiers, across multiple markets and debottleneck Unit I
Slide 42: Rs. 571 Crore Capex Across Four Projects
Rs. 571 Crore Capex Across Four Projects 1 2 3 4 Rs. 215 cr Rs. 27 cr Rs. 18 cr Rs. 311 cr Indian injectable Unit III and Research and Adelaide, Australia and oral capacity* Unit IV upgradation development centre* Rs. 83.83 crore as 60% equity in Rs. 27.0 crore towards the Unit III Rs. 15.0 crore fo
Slide 43: The Regulated Market Roadmap
The Regulated Market Roadmap THE REGULATED Replacing - MARKET a constrained ROADMAP injectable base with a new EU-GMP facility, then extending into cephalosporins and biologics. Oral solids October 2026 UNIT III To be expanded from 240 to 451 million units to absorb volume Noumed places with third p
Slide 44: Acquisition Track Record and Framework
Acquisition Track Record and Framework Year Acquisition Consideration What we bought Strategic rationale TGA-Australia and PIC/S Expand footprint in regulated markets OUR ASSESSMENT FRAMEWORK FY22 Unit III, Bhongir Rs. 24 cr accredited oral solids facility and enhance manufacturing capacity Strategi
Slide 45: Key Milestones and Priorities
Key Milestones and Priorities Key Milestones for FY27 Completion of the capital programme, shareholders' approval of the proposed variation of utilization of IPO proceeds and the integration of Noumed are the immediate milestones over the next twelve months Sept 2026 Oct 2026 Jan 2027 Jan–Feb 2027 M
Slide 46: Outlook: FY27 and FY28
Outlook: FY27 and FY28 FY27 · EXECUTION-FOCUSED GROWTH YEAR FY28 · INFLECTION POINT AS INVESTMENTS MONETISE Rs. 750 crore ~17%* From asset build to monetisation Revenue Target EBITDA margin • Saicriti lifts injectable capacity to ~154.66 mn units, supported by the acquired Driven by existing long-te
Slide 47: Financial Highlights – Q1FY27
Financial Highlights – Q1FY27
Slide 48: Management Commentary
Management Commentary “Q1FY27 marked a solid start to the year, with consolidated revenue of ₹2.4 crore, representing approximately 24% of the FY27 revenue target of ₹750 crore and ahead of the required run-rate given the company’s seasonally H2-weighted business. Gross margin improved to 41.8% from
Slide 49: Key Highlights
Key Highlights IPO proceeds redeployed towards strategic assets 1 Rs. 101.85 crore proposed to be invested in majority stakes in Saicriti Pharma and Prathyak Laboratories, subject to shareholder approval 60% stake in Saicriti Pharma proposed 2 Rs. 83.83 crore investment towards a ₹215 crore EU-GMP/U
Slide 50: Financial Highlights
Financial Highlights Total Revenue (Rs. Cr) EBITDA (Rs. Cr) & Margin (%) PAT (Rs. Cr) & Margin (%) Standalone +175% +292.7% +975.1% 56 17 9 20 4 20.9% 29.8% 1 15.8% Q1FY26 Q1FY27 Q1FY26 Q1FY27 4.0% Q1FY26 Q1FY27 Total Revenue (Rs. Cr) EBITDA (Rs. Cr) & Margin (%) PAT (Rs. Cr) & Margin (%) Consolidat
Slide 51: Standalone Profit & Loss Statement
Standalone Profit & Loss Statement Particulars (Rs. in crore) Q1FY27 Q1FY26 YoY Q4FY26 QoQ FY26 Revenue from Operations 52.8 19.2 174.9% 56.8 -7.1% 162.3 Other Income 3.4 1.2 0.1 2.7 Total Revenue 56.2 20.4 174.8% 56.9 -1.3% 165.0 Total Raw Material 34.1 10.7 37.4 104.2 Gross Profit 22.1 9.8 126.5%
Slide 52: Consolidated Profit & Loss Statement
Consolidated Profit & Loss Statement Particulars (Rs. in crore) Q1FY27 Q1FY26 YoY Q4FY26 QoQ FY26 Revenue from Operations 178.7 33.4 435.1% 197.9 -9.7% 381.0 Other Income 3.7 1.2 2.9 8.5 Total Revenue 2.4 34.6 427.8% 200.8 -9.2% 389.5 Total Raw Material 106.2 21.9 124.3 242.2 Gross Profit 76.2 12.7
Slide 53: Historical Financial Highlights
Historical Financial Highlights
Slide 54: Consolidated Financial Highlights
Consolidated Financial Highlights Revenue from operations (Rs. Cr) EBITDA (Rs. Cr) & Margin (%) PAT (Rs. Cr) & Margin (%) 381 +30% +48% +58% 39 39 14 14 32 163 8 154 18 97 4 18.2% 20.6% 24.1% 10.2% 4.5% 5.5% 8.8% 3.7% FY23 FY24 FY25 FY26* FY23 FY24 FY25 FY26* FY23 FY24 FY25 FY26* ROCE (%) ROE (%) Ne
Slide 55: Consolidated Profit & Loss Statement
Consolidated Profit & Loss Statement Particulars (Rs. in crore) FY26* FY25 FY24 FY23 Revenue from Operations 381.0 163.1 153.8 96.8 Total Raw Material 242.2 93.9 94.9 57.8 Gross Profit 138.8 69.3 58.8 39.0 GP Margin (%) 36.4% 42.5% 38.3% 40.2% Employee expense 29.3 13.1 12.6 8.9 Other expenses 70.8
Slide 56: Consolidated Balance Sheet
Consolidated Balance Sheet Particulars (Rs. in crore) FY26* FY25 FY24 FY23 Particulars (Rs. in crore) FY26* FY25 FY24 FY23 ASSETS Equity Non-current assets Equity Share capital 22.1 13.3 13.2 7.2 Property, plant and equipment 61.6 43.4 60.1 43.5 Equity Attributable to Parent 468.7 80.4 61.3 24.3 129
Slide 57: Consolidated Cash Flow Statement
Consolidated Cash Flow Statement Particulars (Rs. in crore) FY26* FY25 FY24 FY23 Net Profit Before Tax 11.9 19.9 12.6 7.3 Adjustments for: Non Cash Items / Other Investment or Financial Items 30.5 20.4 20.7 11.6 Operating profit before working capital changes 42.5 40.3 33.2 .8 Changes in working cap
Slide 58: Thank You
Thank You Company Investor Relations Advisors CIN: U24231TG2001PLC036043 CIN: U74140MH2010PTC204285 Mr. Anil Kumar, Chief Financial Officer Ms. Drashti Shah / Mr. Parin Narichania +91 87672 24443 / +91 99300 25733 ir@saiparenterals.com drashti.shah@sgapl.net / parin.n@sgapl.net saiparenterals.com ww